GSK says long-act­ing asth­ma treat­ment clears two Phase 3 stud­ies

GSK an­nounced Tues­day morn­ing that its ex­per­i­men­tal an­ti­body treat­ment re­duced the year­ly rate of asth­ma at­tacks across two key clin­i­cal tri­als for ado­les­cents and adults …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER